Dan Rose is the founder of LimFlow SA. Latest round: Series D. Backed by Longitude Capital, Soleus Capital Management, Sofinnova Partners.
Dan Rose is the CEO of LimFlow SA, a company developing minimally-invasive technology for treating chronic limb-threatening ischemia (CLTI), a severe form of peripheral artery disease. The LimFlow System is designed to prevent amputations in CLTI patients. LimFlow SA recently raised $40 million in Series D financing to support its clinical program and commercialization efforts.
Full founder directory · Investor directory · Company funding database · Fundraising library